<\/p>\n
There is a pattern to how Cathie Wood exits positions. It rarely happens in one move. It happens in layers, a little here, a little there, until you look back and realize ARK has been sending a signal for weeks. That pattern is playing out right now with Twist Bioscience (TWST).<\/p>\n
On May 12, ARK sold 56,429 shares of TWST across its ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG), valued at approximately $3.17 million, according to Wood’s Ark’s published daily trade disclosures. <\/p>\n
This continues a consistent reduction in the position over the past week. TWST is up 75.41% year to date and 72.31% over the past year, as of writing, according to Yahoo Finance – a strong run by any measure.<\/p>\n
The sell is not a panic move. ARK is trimming a winner. But the consistency of the reduction raises a question worth exploring. With Twist Bioscience reporting 13 consecutive quarters of revenue growth and approaching EBITDA breakeven, according to their Q2 2026 earnings report, why is Wood pulling back now?<\/p>\n
What Twist Bioscience’s latest earnings show<\/p>\n
Before getting to the exit thesis, the business case for Twist deserves a fair read.<\/p>\n
Twist Bioscience reported fiscal second-quarter 2026 results on May 4, delivering its 13th consecutive quarter of sequential revenue growth. That\u2019s a streak that is genuinely rare in biotech.\u00a0<\/p>\n
Twist Bioscience Q2 2026 Key results:Revenue of $110.7 million, up 19% year over year.Gross margin of 51.6%, up approximately 2 percentage points versus the same period last year.DNA Synthesis and Protein Solutions revenue up 28% year over year to $53.3 million.NGS Applications revenue up 12% year over year to $57.4 million.Adjusted EBITDA of negative $13.3 million, improving from negative $14.8 million last year.Cash position of approximately $172 million as of March 31, 2026.
\nSource: Twist Bioscience Fiscal Second Quarter 2026 Financial Results<\/p>\n
The company raised its full-year fiscal 2026 revenue guidance to $442 to $447 million, up from $435 to $440 million previously. <\/p>\n
Management reiterated its target of achieving adjusted EBITDA breakeven in the fourth quarter – a milestone that would mark a genuine inflection in Twist’s financial profile.<\/p>\n
“We remain focused on delivering consistent, measurable growth designed to scale over time,” said CEO Emily Leproust. “We continue to anticipate achieving adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.”<\/p>\n
Twist Bioscience reported fiscal second-quarter 2026 results on May 4, delivering its 13th consecutive quarter of sequential revenue growth.<\/p>\n
Smith Collection/Gado/Getty Images<\/p>\n
Strategic moves that make Twist more interesting, and the ARK exit more surprising<\/p>\n
My review of the recent highlights from Twist’s earnings release reveals a company making the right kinds of partnerships at the right moment.<\/p>\n
Amazon Web Services named Twist as a wet lab partner for Amazon Bio Discovery, the company’s AI-powered drug discovery application. That is not a small development. Being embedded in AWS’s drug discovery infrastructure gives Twist access to a pipeline of pharmaceutical and biotech customers that could meaningfully accelerate its commercial trajectory.<\/p>\n
Related: Cathie Wood buys $12.9 million of tumbling tech stock<\/p>\n
Twist also entered a bispecific licensing agreement to become a co-exclusive provider of Invenra’s B-Body bispecific antibody platform, expanding its antibody discovery services. The company shipped products to approximately 2,583 customers in the quarter, up from 2,431 in the same period last year, and physically shipped approximately 300,000 genes, up from 227,000 previously, according to the earnings statement.<\/p>\n
These are not the metrics of a company losing momentum. They are the metrics of a company gaining it, which makes ARK’s consistent selling more nuanced than it might appear on the surface.<\/p>\n
Why ARK may be rotating out of TWST despite strong fundamentals<\/p>\n
ARK does not comment publicly on individual trades. But my review of the broader pattern across ARK’s recent activity tells a coherent story.<\/p>\n
Wood has been rotating aggressively in May, selling positions that have run hard and redeploying into names she views as having more asymmetric upside ahead. Advanced Micro Devices (AMD) was trimmed after a massive run. TWST, up 75% year to date, fits that same profile. The position may simply have grown large enough relative to ARK’s conviction level that trimming makes portfolio sense regardless of the business quality.<\/p>\n
ARK simultaneously purchased 40,000 shares of Intellia Therapeutics (NTLA) valued at approximately $576,800 and 4,310 shares of Natera (NTRA) totaling $858,293, according to Cathie\u2019s Ark daily disclosures. That continues a strategic accumulation of gene-editing and precision medicine names that appear to be ARK’s higher-conviction biotech bets at this moment.<\/p>\n
More Fund manager buys and sells<\/p>\n
Cathie Wood buys $2.5 million of tumbling megacap stockWarren Buffett dumped 77% of Amazon to buy surging media stockCathie Wood buys $11 million of tumbling megacap tech stock<\/p>\n
The capital is not leaving biotech. It is being redistributed within it toward earlier-stage, higher-upside names where ARK’s long-duration investment thesis plays out more fully.<\/p>\n
For investors holding TWST, the ARK trim is a yellow flag, not a red one. A company delivering 13 consecutive quarters of growth and approaching its first EBITDA-positive quarter does not sell itself. But when the market’s most visible growth investor begins to reduce a position consistently, it is worth asking whether the easy gains are already behind you.<\/p>\n
Related: Cathie Wood sells another $15.6M of surging semiconductor stock<\/p>\n
#Cathie #Wood #trims #3.17M #surging #bioscience #stock<\/p>\n","protected":false},"excerpt":{"rendered":"
There is a pattern to how Cathie Wood exits positions. It rarely happens in one…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[259],"tags":[11995,11996,3417,91,4061,6608,3418],"_links":{"self":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/6274"}],"collection":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6274"}],"version-history":[{"count":0,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/6274\/revisions"}],"wp:attachment":[{"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}